The US Food and Drug Administration (FDA) has approved Boston Scientific’s expanded instructions for use (IFU) labelling of ...

Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, ...

Boston Scientific has claimed a new approval from the FDA for its Farapulse pulsed field ablation system, expanding its use ...

Marlborough: Boston Scientific Corporation has announced that the company has received approval from the U.S. Food and Drug ...

Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval to expand the ...

Boston Scientific (NYSE: BSX) announced that the FDA approved an expansion to the label of its Farapulse pulsed field ...

Boston Scientific Corp. gained a second U.S. FDA approval for its Farapulse pulsed field ablation catheter, expanding its use into drug-refractory, symptomatic persistent atrial fibrillation (AF) in ...

Boston Scientific reported that electrophysiology sales grew 172% in Q4 2024, driven by an uptake of its Farapulse pulsed ...

"These positive study results are an important step forward in the continued innovation of the proven FARAPULSE PFA System and our broader portfolio of products that treat AF," said Brad Sutton, M ...

Trial achieves positive results in the treatment of persistent atrial fibrillation MARLBOROUGH, Mass. and SAN DIEGO, April 24, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today ...

Second phase of ADVANTAGE AF study of FARAPULSE™ Pulsed Field Ablation System meets primary safety and efficacy endpoints. PR Newswire. MARLBOROUGH, Mass. and SAN DIEGO, April 24, 2025.

MARLBOROUGH, Mass. and SAN DIEGO, April 24, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month primary endpoint results from the second phase of the ...